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Abstract
Introduction There are limited head-to-head data com-
paring the efficacy of long-acting amfetamine- and meth-
ylphenidate-based psychostimulants as treatments for
individuals with attention-deficit hyperactivity disorder
(ADHD). This post hoc analysis provides the first parallel-
group comparison of the effect of lisdexamfetamine
dimesylate (lisdexamfetamine) and osmotic-release oral
system methylphenidate (OROS-MPH) on symptoms of
ADHD in children and adolescents.
Study Design This was a post hoc analysis of a ran-
domized, double-blind, parallel-group, dose-optimized,
placebo-controlled, phase III study.
Setting The phase III study was carried out in 48 centres
across ten European countries.
Patients The phase III study enrolled children and ado-
lescents (aged 6–17 years) who met Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition,
Text Revision criteria for a primary diagnosis of ADHD
and who had a baseline ADHD Rating Scale IV (ADHD-
RS-IV) total score of 28 or higher.
Intervention Eligible patients were randomized (1:1:1) to
receive a once-daily, optimized dose of lisdexamfetamine
(30, 50 or 70 mg/day), placebo or OROS-MPH (18, 36 or
54 mg/day) for 7 weeks.
Main Outcome Measures In this post hoc analysis, effi-
cacy was assessed using the ADHD-RS-IV and Clinical
Global Impressions-Improvement (CGI-I) scale. Respond-
ers were defined as those achieving at least a 30 %
reduction from baseline in ADHD-RS-IV total score and
a CGI-I score of 1 (very much improved) or 2 (much
improved). The proportion of patients achieving an
ADHD-RS-IV total score less than or equal to the mean for
their age (based on normative data) was also determined.
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Endpoint was the last on-treatment visit with a valid
assessment. Safety assessments included treatment-emer-
gent adverse events (TEAEs) and vital signs.
Results Of the 336 patients randomized, 332 were
included in the safety population, 317 were included in the
full analysis set and 196 completed the study. The mean
(standard deviation) ADHD-RS-IV total score at baseline
was 40.7 (7.31) for lisdexamfetamine, 41.0 (7.14) for pla-
cebo and 40.5 (6.72) for OROS-MPH. The least-squares
(LS) mean change (standard error) in ADHD-RS-IV total
score from baseline to endpoint was -24.3 (1.16) for lis-
dexamfetamine, -5.7 (1.13) for placebo and -18.7 (1.14)
for OROS-MPH. The difference between lisdexamfetamine
and OROS-MPH in LS mean change (95 % confidence
interval [CI]) in ADHD-RS-IV total score from baseline to
endpoint was statistically significant in favour of lis-
dexamfetamine (-5.6 [-8.4 to -2.7]; p \ 0.001). The
difference between lisdexamfetamine and OROS-MPH in
the percentage of patients (95 % CI) with a CGI-I score of
1 or 2 at endpoint was 17.4 (5.0–29.8; p \ 0.05; number
needed to treat [NNT] 6), and the difference in the per-
centage of patients (95 % CI) achieving at least a 30 %
reduction in ADHD-RS-IV total score and a CGI-I score of
1 or 2 was 18.3 (5.4–31.3; p \ 0.05; NNT 6). The differ-
ence between lisdexamfetamine and OROS-MPH in the
percentage of patients (95 % CI) with an ADHD-RS-IV
total score less than or equal to the mean for their age at
endpoint was 14.0 (0.6–27.4; p = 0.050). The overall fre-
quency of TEAEs and the frequencies of decreased appe-
tite, insomnia, decreased weight, nausea and anorexia
TEAEs were greater in patients treated with lisdexamfe-
tamine than in those treated with OROS-MPH, whereas
headache and nasopharyngitis were more frequently
reported in patients receiving OROS-MPH.
Conclusions This post hoc analysis showed that, at the
doses tested, patients treated with lisdexamfetamine
showed statistically significantly greater improvement in
symptoms of ADHD than those receiving OROS-MPH, as
assessed using the ADHD-RS-IV and CGI-I. The safety
profiles of lisdexamfetamine and OROS-MPH were con-
sistent with the known effects of stimulant medications.
1 Introduction
Amfetamine- and methylphenidate-based stimulants are
effective pharmacological treatments for individuals with
attention-deficit hyperactivity disorder (ADHD), which is one
of the most common neurodevelopmental disorders among
school-aged children [1–3]. These pharmacotherapies have
consistently been found to reduce the symptoms of inatten-
tion, hyperactivity and/or impulsivity, as well as the func-
tional impairments that are associated with ADHD [4, 5].
Long-acting stimulant formulations were developed to
provide extended control of ADHD symptoms throughout
the day [6]. Lisdexamfetamine dimesylate (lisdexamfeta-
mine) and osmotic-release oral system methylphenidate
(OROS-MPH) were both designed to facilitate once-daily
dosing. Lisdexamfetamine is the first long-acting prodrug
stimulant. It is metabolized primarily in the bloodstream
after absorption from the gastrointestinal tract, yielding
therapeutically active d-amfetamine [7, 8]. OROS-MPH
capsules deliver the active drug, racemic methylphenidate,
in the gastrointestinal tract in a biphasic manner [9].
Therapeutic benefits have been shown to persist for
13–14 h with lisdexamfetamine [10, 11] and 12.5 h [12]
with OROS-MPH. A recent meta-analysis provided indi-
rect evidence that stimulants based on amfetamine may
have slightly greater efficacy than those based on methyl-
phenidate in reducing symptoms of ADHD in children and
adolescents [1]. However, to date, no published, parallel-
group studies have directly compared the efficacy of lis-
dexamfetamine and OROS-MPH.
Study SPD489-325 was a European, 7-week, phase III,
randomized study that evaluated the efficacy and safety of
lisdexamfetamine in children and adolescents with ADHD
[13]. The study utilised a three-arm design that included a
placebo control and an active reference arm, as required by
the European Medicines Agency [14]. Lisdexamfetamine
and the active comparator, OROS-MPH, were shown to be
more effective than placebo in reducing symptoms of
ADHD, as assessed using the ADHD Rating Scale IV
(ADHD-RS-IV) and the Clinical Global Impressions-
Improvement scale (CGI-I) [13]. Improvements in ADHD-
RS-IV total score from baseline to endpoint were associ-
ated with large effect sizes for lisdexamfetamine (1.80) and
OROS-MPH (1.26), indicating robust treatment responses.
Although study SPD489-325 was neither planned nor
powered for a primary statistical comparison between the
two active treatment arms, the present post hoc analysis
was conducted to compare the effect of lisdexamfetamine
and OROS-MPH on symptoms of ADHD in children and
adolescents.
2 Methods
The experimental procedures used in this randomized,
double-blind, parallel-group, dose-optimized, placebo-
controlled, phase III study have been described previously
[13]. The study protocol (ClinicalTrials.gov ID:
NCT00763971) was approved by an independent ethics
committee/institutional review board and regulatory
agency in each centre (as appropriate) before study initia-
tion. The study was conducted in accordance with current
international and local applicable regulations, and written
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informed consent was obtained from each participant or
their legally appointed representative.
2.1 Patients and Study Design
The study was conducted in 48 centres across ten European
countries and enrolled male and female children (aged
6–12 years) and adolescents (aged 13–17 years) who met
the Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision (DSM-IV-TR) criteria for a
primary diagnosis of ADHD. Patients were required to
have an investigator-rated, baseline ADHD-RS-IV total
score of 28 or higher. Enrolment was managed so that
adolescents (aged 13–17 years) accounted for approxi-
mately 25 % of the study population.
Eligible patients completed a screening and washout
period (3–42 days, depending on previous medication) and
were randomized (1:1:1) to receive once-daily lis-
dexamfetamine, placebo or OROS-MPH. The double-blind
evaluation period consisted of a 4-week dose-optimization
period, followed by a 3-week dose-maintenance period,
and a 1-week washout and safety follow-up.
Three doses of lisdexamfetamine (30, 50 and 70 mg/
day) and OROS-MPH (18, 36 and 54 mg/day) were used in
this study. OROS-MPH was administered according to
European regulations (maximum licensed dose, 54 mg/
day) [15]. Dosing began at approximately 07:00 h on the
morning after completion of the baseline visit. Patients
initially received lisdexamfetamine 30 mg/day, placebo or
OROS-MPH 18 mg/day. If an acceptable response to
treatment was not achieved, adjustments to higher doses
were to be made at weekly intervals during the dose-opti-
mization period. An acceptable response was defined as a
reduction of at least 30 % in ADHD-RS-IV total score
from baseline and a CGI-I score of 1 (very much improved)
or 2 (much improved), with tolerable adverse effects. One
dose reduction was permitted during the optimization
period if a patient experienced an intolerable adverse
effect. Doses could not be modified after visit 3; patients
unable to tolerate the study drug after visit 3 were with-
drawn from the study. Patients achieving an acceptable
response continued on their optimal dose for the remainder
of the double-blind evaluation period.
2.2 Efficacy Outcomes
The primary efficacy outcome measure of SPD489-325 was
the investigator-rated ADHD-RS-IV total score, which was
assessed at baseline and at each weekly study visit there-
after. The key secondary efficacy outcome measure was the
investigator-rated CGI-I, which was used to assess global
improvement at each weekly post-baseline visit. CGI-I
scores were categorized as ‘improved’ (CGI-I of 1 or 2)
or ‘not improved’ (all other scores). A clinically significant
response was defined a priori as at least a 30 % reduction
from baseline in ADHD-RS-IV total score and a CGI-I
score of 1 or 2 [16]. The proportions of patients achieving
an ADHD-RS-IV total score less than or equal to the mean
for their age, based on normative data, were also
determined.
2.3 Safety Outcomes
Safety outcomes were assessed for the safety population,
defined as all patients who took at least one dose of study
drug. Safety assessments included, but were not limited to,
evaluation of treatment-emergent adverse events (TEAEs),
clinical laboratory parameters, vital signs and electrocar-
diograms, as well as physical examinations. An adverse
event was defined as treatment emergent if the event started
or worsened in the period between the first dose of study
drug and the third day (inclusive) following cessation of
treatment. TEAEs were coded using the current version of
the Medical Dictionary for Regulatory Activities (version
11.1) and summarized by system organ class, preferred
term and treatment group for the number and proportion
reporting the event.
2.4 Statistical Analyses
Although not pre-specified in the statistical analysis plan
for SPD489-325, a post hoc statistical analysis was con-
ducted to compare the effect of lisdexamfetamine and
OROS-MPH on symptoms of ADHD, as assessed using the
ADHD-RS-IV and CGI-I.
Efficacy outcomes were assessed for the full analysis
set, defined as all patients who were randomized and took
at least one dose of study drug. Patients from one site
(n = 15) were excluded from the full analysis set as a
consequence of violations of Good Clinical Practice. The
change from baseline in the ADHD-RS-IV total score was
analysed using an analysis of covariance (ANCOVA)
model. Least squares (LS) means and p values were based
on type III sum of squares from the ANCOVA model for
the change from baseline, including treatment group (effect
of interest), country and age group (randomization block-
ing factors) and the corresponding baseline score (covari-
ate). Effect sizes based on the change in ADHD-RS-IV
total score from baseline were calculated as the difference
in LS mean score between treatment arms, divided by the
root mean square error obtained from the ANCOVA
model. The number and percentage of patients categorized
as ‘improved’ (CGI-I of 1 or 2) at each post-baseline study
visit and at endpoint was summarized by treatment group,
and each active treatment group compared with placebo
using a Cochran–Mantel–Haenszel test stratified by
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country and age group. The percentage of patients meeting
each responder criterion at endpoint was also analysed
using a Cochran–Mantel–Haenszel test stratified by coun-
try and age group. The number needed to treat (NNT) was
calculated as the inverse of the difference in proportions
between the treatment groups. The endpoint for all out-
come measures was the last on-treatment, post-baseline
visit with a valid assessment.
Safety data are summarized for the safety population




Of the 336 patients who were randomized, 332 were
included in the safety population (lisdexamfetamine,
n = 111; placebo, n = 110; OROS-MPH, n = 111), 317
were included in the full analysis set (lisdexamfetamine,
n = 104; placebo, n = 106; OROS-MPH, n = 107) and
196 completed the study (lisdexamfetamine, n = 80; pla-
cebo, n = 42; OROS-MPH, n = 74). Patient demograph-
ics and baseline characteristics were similar across
treatment groups (Table 1).
3.2 Efficacy Outcomes
At baseline, mean ADHD-RS-IV total scores (standard
deviation [SD]) were similar across treatment groups (lis-
dexamfetamine 40.7 [7.31]; placebo 41.0 [7.14]; OROS-
MPH 40.5 [6.72]) [13]. The LS mean change (standard
error) in ADHD-RS-IV total score from baseline to end-
point was -24.3 (1.16) for lisdexamfetamine, -5.7 (1.13)
for placebo and -18.7 (1.14) for OROS-MPH [13]. The
difference (active drug minus placebo) in the LS mean
change in ADHD-RS-IV total score was statistically sig-
nificant for lisdexamfetamine (p \ 0.001; effect size 1.80)
and OROS-MPH (p \ 0.001; effect size 1.26) (Table 2)
[13]. The percentage of patients (95 % CI) with a CGI-I
score of 1 or 2 at endpoint was 78.0 % (69.9–86.1) for
lisdexamfetamine, 14.4 % (7.7–21.2) for placebo and
60.6 % (51.2–70.0) for OROS-MPH. The difference
(active drug minus placebo) in the percentage of patients
with a CGI-I score of 1 or 2 was statistically significant for
lisdexamfetamine (p \ 0.001; NNT 2) and OROS-MPH
(p \ 0.001; NNT 3) (Table 2) [13].
A clinically significant response to treatment was defined
a priori as at least a 30 % reduction from baseline in ADHD-
RS-IV total score and a CGI-I score of 1 or 2. At endpoint,
the percentage of patients (95 % CI) categorized as
responders was 74.2 % (65.5–82.9) for lisdexamfetamine,
10.7 % (4.7–16.6) for placebo and 55.9 % (46.2–65.5) for
OROS-MPH. The difference (active drug minus placebo) in
the percentage of responders was statistically significant for
lisdexamfetamine (p \ 0.001; NNT 2) and OROS-MPH
(p \ 0.001; NNT 3) (Table 2).
Responders were also defined a posteriori as those
achieving an ADHD-RS-IV total score less than or equal to
the mean for their age. At endpoint, the percentage of
patients (95 % CI) meeting this second responder criterion
was 65.0 % (55.7–74.3) for lisdexamfetamine, 14.4 %
(7.7–21.2) for placebo and 51.0 % (41.4–60.6) for OROS-
MPH. The difference (active drug minus placebo) in the
percentage of responders was statistically significant for
lisdexamfetamine (p \ 0.001; NNT 2) and OROS-MPH
(p \ 0.001; NNT 3) (Table 2).
The post hoc analysis showed a statistically significant
difference between lisdexamfetamine and OROS-MPH, in
favour of lisdexamfetamine, in the LS mean change in








Age, years, mean (SD) 10.9 (2.9) 11.0 (2.8) 10.9 (2.6)
Sex, male, n (%) 87 (78.4) 91 (82.7) 90 (81.1)
Race, white, n (%) 107 (96.4) 108 (98.2) 107 (96.4)
BMI, kg/m2, mean (SD) 19.3 (3.7) 19.0 (3.3) 19.1 (3.2)
Baseline ADHD-RS-IV
total score, mean (SD)b
41.0 (7.3) 41.2 (7.2) 40.4 (6.8)
ADHD subtype, n (%)c
Predominantly
inattentive
23 (20.7) 16 (14.5) 14 (12.7)
Predominantly
hyperactive-impulsive
2 (1.8) 7 (6.4) 1 (0.9)
Combined 86 (77.5) 87 (79.1) 95 (86.4)
Concomitant psychiatric
diagnosis, n (%)d
Any 19 (17.1) 20 (18.2) 29 (26.1)
Oppositional defiant
disorder
8 (7.2) 8 (7.3) 10 (9.0)
a Demographic and baseline characteristics have previously been
reported in detail [13]
b Five patients had no baseline ADHD-RS-IV total score
c One patient in the OROS-MPH group was not evaluated for ADHD
subtype. Percentages are based on the number of patients in each
treatment group
d Patients with at least one ongoing definite psychiatric diagnosis
based on the Kiddie Schedule for Affective Disorders and Schizo-
phrenia for school age children—present and lifetime diagnostic
interview. A patient could have more than one diagnosis
ADHD attention-deficit hyperactivity disorder; ADHD-RS-IV ADHD
Rating Scale IV, BMI body mass index, LDX lisdexamfetamine
dimesylate, OROS-MPH osmotic-release oral system methylpheni-
date, SD standard deviation
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ADHD-RS-IV total score from baseline to endpoint
(p \ 0.001; effect size 0.54), in the percentage of patients
with a CGI-I score of 1 or 2 at endpoint (p \ 0.05; NNT 6)
and in the percentage of patients achieving at least a 30 %
reduction from baseline in ADHD-RS-IV total score and a
CGI-I score of 1 or 2 at endpoint (p \ 0.05; NNT 6)
(Table 2). At endpoint, the difference between lis-
dexamfetamine and OROS-MPH in the percentage of
patients with an ADHD-RS-IV total score less than or
equal to the mean for their age was not statistically sig-
nificant (p = 0.050; Table 2).
3.3 Safety Outcomes
Safety outcomes have been reported in detail previously
[13]. Most patients in the safety population reported one or
more TEAEs (Table 3). Of the TEAEs reported in at least
10 % of patients in any treatment group, those that
occurred at a numerically greater frequency in the lis-
dexamfetamine group than in the OROS-MPH group were
decreased appetite, insomnia, decreased weight, nausea and
anorexia; headache and nasopharyngitis were more fre-
quently reported in the OROS-MPH group than in the
lisdexamfetamine group (Table 3). The proportion of
patients reporting serious adverse events was low across all
treatment groups (lisdexamfetamine 2.7 %; placebo 2.7 %;
OROS-MPH 1.8 %). Few patients experienced TEAEs
leading to discontinuation of study drug (lisdexamfetamine
4.5 %; placebo 3.6 %; OROS-MPH 1.8 %).
Patients treated with lisdexamfetamine and OROS-MPH
reported modest increases from baseline to endpoint in
mean (SD) pulse rate (lisdexamfetamine ?5.5 [13.2] bpm;
placebo -0.6 [10.6] bpm; OROS-MPH ?3.4 [13.2] bpm),
heart rate (lisdexamfetamine ?5.7 [15.3] bpm; placebo
-1.1 [9.6] bpm; OROS-MPH ?5.0 [12.8] bpm), systolic
blood pressure (lisdexamfetamine ?1.0 [9.8] mmHg; pla-
cebo ?1.0 [9.6] mmHg; OROS-MPH ?0.3 [11.1] mmHg),
and diastolic blood pressure (lisdexamfetamine ?0.2
[9.6] mmHg; placebo ?1.2 [8.7] mmHg; OROS-MPH
?1.7 [9.9] mmHg) [13]. Changes in mean (SD) body
weight from baseline to endpoint were as follows: lis-
dexamfetamine -2.1 [1.9] kg; placebo ?0.7 [1.0] kg;
OROS-MPH -1.3 [1.4] kg) [13]. Of the 47 patients (lis-
dexamfetamine, n = 35; OROS-MPH, n = 12) who had a
potentially clinically significant decrease in weight at
endpoint (defined as C7 % from baseline), three patients
(lisdexamfetamine, n = 2; OROS-MPH, n = 1) moved
from a body mass index (BMI) category of healthy weight
low (BMI from 5th to 25th percentile) or healthy weight
high (BMI from 25th to 85th percentile) to underweight
(BMI less than the 5th percentile).
Table 2 Summary of efficacy outcomes for lisdexamfetamine
dimesylate and osmotic-release oral system methylphenidate in chil-












Difference in LS mean
change in ADHD-RS-IV
total score from baseline
to endpoint
-18.6 -13.0 -5.6






p value \0.001 \0.001 \0.001






95 % CI 53.0–74.1 34.6–57.7 5.0–29.8
p value \0.001 \0.001 \0.05
NNT 2 3 6
Responders (‡30 % reduction from baseline in ADHD-RS-IV





95 % CI 53.0–74.1 33.9–56.5 5.4–31.3
p value \0.001 \0.001 \0.05
NNT 2 3 6





95 % CI 39.0–62.1 24.8–48.3 0.6–27.4
p value \0.001 \0.001 0.050
NNT 2 3 8
p values are based on the difference between active drug and placebo
(predefined comparison) and the difference between LDX and OROS-
MPH (post hoc comparison). Data are provided for the full analysis
set: LDX (n = 104); placebo (n = 106); OROS-MPH (n = 107). All
percentages are based on the number of patients with data at that visit
in each treatment group. Endpoint was the last on-treatment, post-
baseline visit with a non-missing assessment
a A decrease from baseline in the ADHD-RS-IV total score indicates
an improvement in ADHD symptoms
b Improvement was defined as a CGI-I score of 1 (very much
improved) or 2 (much improved)
c Responder analysis based on normative data
ADHD attention-deficit hyperactivity disorder; ADHD-RS-IV ADHD
Rating Scale IV, CGI-I Clinical Global Impressions-Improvement, CI
confidence interval, LDX lisdexamfetamine dimesylate, LS least
squares, NNT number needed to treat, OROS-MPH osmotic-release
oral system methylphenidate
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4 Discussion
In this post hoc analysis of data from a European, 7-week,
phase III study (SPD489-325), children and adolescents
treated with lisdexamfetamine showed statistically signifi-
cantly greater improvements in ADHD-RS-IV total score
and CGI-I score from baseline to endpoint than those
treated with OROS-MPH. In addition, a greater proportion
of patients receiving lisdexamfetamine were categorized as
responders at study endpoint than those receiving OROS-
MPH. These findings suggest that, at the doses tested, lis-
dexamfetamine produced greater improvements in the
symptoms of ADHD in children and adolescents than
OROS-MPH.
To date, there has only been one published parallel-
group comparison of stimulant medications for the treat-
ment of individuals with ADHD [17]. In this study, mixed
amfetamine salts were found to produce significantly
greater improvements in teacher ratings and CGI-I scores
than short-acting methylphenidate [17]. Several crossover
studies have investigated the comparative efficacies of
short-acting methylphenidate- and amfetamine-based
stimulants, but no consistent differences have emerged [2].
However, a meta-analysis of randomized controlled trials
of both short- and long-acting formulations found that
effect sizes for amfetamine-based stimulants were moder-
ately, but statistically significantly, greater than those for
methylphenidate [1]. While SPD489-325 was not pro-
spectively designed or powered to compare the clinical
profiles of the two active treatment arms, this post hoc
analysis has provided the first parallel-group comparison of
the efficacy of the long-acting stimulants, lisdexamfeta-
mine and OROS-MPH. Although both treatments produced
robust responses, improvements in symptoms were greater
for lisdexamfetamine than for OROS-MPH.
In the present study, patients who were randomized to the
lisdexamfetamine treatment group received 30, 50 or
70 mg/day. OROS-MPH was administered according to
European regulations (maximum licensed dose, 54 mg/day).
The study included a 3-week dose-optimization period,
suggesting that the doses of lisdexamfetamine and OROS-
MPH were less likely to have influenced their relative
efficacy. However, it is notable that a higher proportion of
patients was optimized to the highest available dose
of OROS-MPH (18 mg/day, 9.9 %; 36 mg/day, 19.8 %;
54 mg/day, 53.2 %) than to the highest available dose of
lisdexamfetamine (30 mg/day, 18.0 %; 50 mg/day, 29.7 %;
70 mg/day, 33.3 %) [13]. Furthermore, the proportion of
patients who were discontinued from the study due to lack
of efficacy was greater for OROS-MPH than for lis-
dexamfetamine [13]. Therefore, it is possible that treatment
responses were dose limited in more patients receiving
OROS-MPH than in those receiving lisdexamfetamine.
There is little evidence to suggest that differences in the
baseline patient characteristics contributed to the observed
differences in treatment responses to lisdexamfetamine and
OROS-MPH. Patients were randomized to receive lis-
dexamfetamine, placebo or OROS-MPH, and patient
demographics and baseline disease characteristics were
similar across treatment groups [13]. Although the pro-
portion of patients with the predominantly inattentive
subtype was numerically greater for lisdexamfetamine than
for OROS-MPH, most patients across all treatment groups
had the combined ADHD subtype, and previous analyses
revealed that improvements in both the hyperactivity/
impulsivity and the inattention subscale scores of the
Table 3 Treatment emergent
adverse effects reported by
C5 % of patients in any
treatment group (safety
population)a
a Safety outcomes have
previously been reported in
detail [13]
b TEAEs are presented in order










LDX (n = 111) Placebo (n = 110) OROS-MPH
(n = 111)
Any TEAE 80 (72.1) 63 (57.3) 72 (64.9)
TEAEs (‡5 % of patients in any treatment group)b
Decreased appetite 28 (25.2) 3 (2.7) 17 (15.3)
Headache 16 (14.4) 22 (20.0) 22 (19.8)
Insomnia 16 (14.4) 0 9 (8.1)
Decreased weight 15 (13.5) 0 5 (4.5)
Nausea 12 (10.8) 3 (2.7) 8 (7.2)
Anorexia 12 (10.8) 2 (1.8) 6 (5.4)
Nasopharyngitis 8 (7.2) 8 (7.3) 14 (12.6)
Upper abdominal pain 8 (7.2) 6 (5.5) 9 (8.1)
Abdominal pain 6 (5.4) 6 (5.5) 4 (3.6)
Sleep disorder 6 (5.4) 1 (0.9) 2 (1.8)
Cough 3 (2.7) 0 8 (7.2)
Initial insomnia 3 (2.7) 1 (0.9) 7 (6.3)
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ADHD-RS-IV in response to lisdexamfetamine and
OROS-MPH treatment were similar [13]. The proportion
of patients with a concomitant, non-exclusionary psychi-
atric diagnosis was greater for OROS-MPH than for lis-
dexamfetamine. However, there was a minimal difference
in the proportions of patients with oppositional defiant
disorder, which has been shown to influence responses to
stimulant treatment [18].
Although the mechanisms of action of stimulants in the
treatment of ADHD remain to be fully established, it is
possible that differences in the pharmacologies of meth-
ylphenidate- and amfetamine-based stimulants contributed
to the differential treatment responses observed for lis-
dexamfetamine and OROS-MPH [19]. Differences in for-
mulation and the resulting pharmacokinetic profiles of
these long-acting stimulants may also have influenced their
therapeutic activity. The pharmacokinetic profile of d-am-
fetamine following administration of lisdexamfetamine is
monophasic, sustained and dose proportional [20]. The
time to maximum observed plasma concentration (Tmax)
and half-life (t) for d-amfetamine following administra-
tion of lisdexamfetamine (30, 50 or 70 mg/day) are
3.41–3.58 h and 8.61–8.90 h, respectively [20]. These
pharmacokinetic properties are reflected in the clinical
duration of action of lisdexamfetamine, which extends to at
least 13 h post-dose in children and 14 h post-dose in
adults [10, 11]. As the metabolism of lisdexamfetamine
occurs mostly in the bloodstream [7], it is unlikely to be
affected by variations in gastric pH or gastrointestinal
transit time [9]. The intra- and inter-patient variability in
pharmacokinetic parameters is low, reflecting predictable
and consistent exposure to d-amfetamine following
administration of lisdexamfetamine [21]. OROS-MPH uses
a mechanical mode of delivery, releasing methylphenidate
in a biphasic manner as it transits through the gastroin-
testinal tract [9]. Approximately 22 % of the overall dose
of methylphenidate is immediately released from the drug
overcoat of the capsule, providing a rapid onset of clinical
efficacy. This is followed by the sustained, osmotically
driven release of methylphenidate. In contrast to lis-
dexamfetamine, alterations in gastrointestinal transit time
and first pass metabolism in the liver may have an impact
on the delivery of methylphenidate from OROS-MPH to
sites of action [9]. Emerging evidence suggests that genetic
factors may also influence treatment responses. To date,
most pharmacogenetic studies of stimulants for ADHD
have focused on genetic variability associated with their
potential mechanism of action and have failed to yield
consistent, clinically relevant findings [22–24]. It is now
also being recognized that genetic variability in carboxy-
lesterase 1A, the principal enzyme responsible for the
metabolism of d,l-methylphenidate to the inactive metab-
olite, ritalinic acid, may have an impact on dose
requirements [25]. Overall, inter- and intra-patient vari-
ability in pharmacokinetic parameters appears to be higher
for OROS-MPH than for lisdexamfetamine [9]. Consistent
with this, although the therapeutic benefits of OROS-MPH
have been shown to last at least 12.5 h [12], clinical
experience suggests that there is considerable variation in
the duration of response [6].
In this study, no new safety signals of concern were
observed and the safety profiles of lisdexamfetamine and
OROS-MPH were similar to the known effects of stimulant
medications [26]. However, it is notable that the overall
frequency of TEAEs and the proportion of patients who
were discontinued from the study due to TEAEs was
numerically greater for lisdexamfetamine than for OROS-
MPH. In addition, certain TEAEs, including decreased
appetite, insomnia, decreased weight, nausea and anorexia,
occurred more frequently in patients treated with lis-
dexamfetamine than in those who received OROS-MPH;
none of these TEAEs were serious [13]. The modest mean
increases from baseline in heart rate, pulse rate, and sys-
tolic and diastolic blood pressure in patients receiving lis-
dexamfetamine and OROS-MPH were also consistent with
the known safety profiles of stimulant medications [26].
Finally, the decrease in mean weight was numerically
greater in the lisdexamfetamine treatment group than in the
OROS-MPH group. However, most patients in both active
treatment groups remained within their baseline BMI cat-
egory and few participants had potentially clinically
important weight changes that resulted in a shift to the
underweight BMI category. Overall, decisions regarding
the choice of ADHD medication for individual patients
should take into account the balance between the benefits
and risks associated with each treatment.
5 Conclusions
In this post hoc analysis of data from a European, ran-
domized, phase III study, children and adolescents with
ADHD who were treated with lisdexamfetamine showed
statistically significantly greater improvements in ADHD-
RS-IV total score and CGI-I score from baseline to end-
point than those treated with OROS-MPH. This suggests
that, at the doses tested, patients treated with lisdexamfe-
tamine showed greater improvements in symptoms of
ADHD than those who received OROS-MPH. The results
of ongoing parallel-group clinical studies (ClinicalTri-
als.gov: NCT01552915 and NCT01552902) [27, 28] will
provide definitive evidence of the comparative therapeutic
efficacy of lisdexamfetamine and OROS-MPH. Mean-
while, the results of the present post hoc analysis support
lisdexamfetamine as a valuable treatment option for the
management of children and adolescents with ADHD.
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